Maximize clinical utility and sensitivity for your patients

Conventional liquid biopsy technologies only allow you to monitor specific genomic variations. NGS promises to expand your view to panels of genes while maintaining high sensitivity and precision. The process, however, is complex and requires a software tailored to your needs.

 

Achieve
maximum performance
with your assays

 

Extensive
onboarding and validation included

 

Comprehensive
quality metrics
and control

Achieving the best analytical performance

When designing an assay several factors must be considered in order to achieve the optimum performance with a specific budget.

Factors that need to be considered when designing an assay


Your clinical application determines the genomic region of interest that should be monitored. The desired limit of detection determines the choice of technology like molecular barcodes. Your budget allows you to sequence at a certain depth. All these factors are interdependent.

Sequencing strategies for different applications

NGS assays are tailored to meet specific requirements. The numbers shown in the table on the right may serve as a guideline. Whichever configuration you choose, the varvis® software allows you to accurately validate your assay and enables you to achieve maximum performance.

Sequencing strategies for different applications

varvis® supports you in every stage of assay development

Liquid biopsy with NGS - Stages of the assay development

 

The validation of NGS assays for liquid biopsy applications may be very complex since they are tailored for the specific task. At the beginning of the onboarding process with varvis®, your assays are validated according to standardized protocols.

Our on-boarding process includes:

  Support in technology selection

  Training

 ​​​​​​​ Validation of assays

Achieve highest performance with barcoding

Molecular barcoding allows to improve sensitivity and precision in NGS assays by many orders of magnitude. While the regular error rate in NGS is of the order of 1/100, barcoding technologies enable us to reduce the error rate to 1/10,000 or even 1/10,000,000. The varvis® software is capable of processing different kinds of molecular barcodes and call variants accurately.

Performance of difference molecular barcoding technologies

Replace conventional CNV detection methods with confidence

In liquid biopsy applications, you are pushing NGS performance to the limit. It is absolutely crucial that you are able to accurately assess and monitor the performance of your laboratory process. The varvis® QC Service provides a wealth of detailed metrics that allow you to determine any deviations from your target performance so that you can react accordingly early on.

Monitor the perfomance of your assays with the varvis® QC service

See for yourself how varvis® can accelerate your laboratory workflows
and increase your diagnostic yield.

Let's schedule a demo

Read more

varvis® blog - Watch now: Sharpening our tools for the diagnosis of mosaic disorders

Watch now: Sharpening our tools for the diagnosis of mosaic disorders

by Nadine Näser, September 9, 2021

In this session, our speakers highlight the specific challenges that physicians encounter while handling mosaic diseases and explain in detail how a suitable assay was established and validated.

Read more

Webinar on-demand: Pushing the boundaries The limit of detection in NGS liquid biopsy

NGS laboratories must comply with numerous regulations and guidelines, and strive, at the same time, to deliver the best possible analytical procedures. In this webinar our three speakers will showcase the latest advancements in NGS liquid biopsy technologies and demonstrate how these novel assays can be properly validated and tailored to the specific use case.

Read more

High-sensitivity solutions for liquid biopsy from NGS

by Ben Liesfeld, August 14, 2020

The varvis® software supports various technologies that allow to use NGS for tumor diagnostics or liquid biopsy applications. This enables our users to detect genomic variants at very low-allele frequencies while monitoring a relatively large genomic region.

Read more

More articles